Exagen Announces Campaign for Lupus Awareness Month
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign
Exagen to Announce First Quarter 2024 Results on May 13, 2024
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before
Exagen: Brian Birk, Ebetuel Pallares, Wendy Johnson to Step Down From Board, Effective June 10 >XGN
Exagen: Brian Birk, Ebetuel Pallares, Wendy Johnson to Step Down From Board, Effective June 10 >XGN
Exagen: Scott Kahn Joining Board >XGN
Exagen: Scott Kahn Joining Board >XGN
Exagen Reducing Size of Board to Seven Directors From Nine >XGN
Exagen Reducing Size of Board to Seven Directors From Nine >XGN
Express News | Exagen Inc. Announces Changes to the Board of Directors
The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New Forecasts
As you might know, Exagen Inc. (NASDAQ:XGN) just kicked off its latest yearly results with some very strong numbers. It looks like a positive result overall, with revenues of US$53m beating forec
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
Exagen Inc.'s (NASDAQ:XGN) 28% Dip In Price Shows Sentiment Is Matching Revenues
Exagen Inc. (NASDAQ:XGN) shareholders won't be pleased to see that the share price has had a very rough month, dropping 28% and undoing the prior period's positive performance. The drop over the la
Exagen Full Year 2023 Earnings: Beats Expectations
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
Exagen's Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth
Q4 2023 Exagen Inc Earnings Call
Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Earnings Call Summary | Exagen(XGN.US) Q4 2023 Earnings Conference
The following is a summary of the Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript:Financial Performance:Exagen reported a record full-year revenue of $52.5 million for 2023, a 15% increase over 202
Exagen Reports Q4 Results
Canopy Growth, Outlook Therapeutics, Immuneering Among Healthcare Movers
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, Vs. Street Est of $11.6M
08:45 AM EDT, 03/18/2024 (MT Newswires) -- Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M
Express News | Exagen Shares Are Trading Higher After the Company Reported Better Than Expected Q4 FY2023 Earnings and Issued FY2024 Guidance
No Data